Evidence map›Paper›PMID 34873463›Full record

ArticleAmerican journal of cancer research2021

ALDH2 is a prognostic biomarker and related with immune infiltrates in HCC.

Senbang Yao, Xiangxiang Yin, Tingting Chen, Wenjun Chen, He Zuo, Ziran Bi, Xiuqing Zhang, Yanyan Jing, Lulian Pang, Huaidong Cheng

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 27 citations in OpenAlex.

  1. Metabolic reprogramming as a key regulator in Helicobacter pylori-infected gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. The biological roles of CD47 in ovarian cancer progression.Cancer immunology, immunotherapy : CII · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Senbang YaoDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Xiangxiang YinDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Tingting ChenDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Wenjun ChenDepartment of Oncology, Anhui Medical University Hefei 230032, Anhui, China.
He ZuoDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Ziran BiDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Xiuqing ZhangDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Yanyan JingDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Lulian PangDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Huaidong ChengDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University Hefei 230601, Anhui, China.
Anhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma is a malignant type of carcinoma with complicated pathogenesis. For HCC patients, there is not only a lack of valuable therapeutic targets, but also a lack of prognostic biomarker. The protein encoded by Aldehyde Dehydrogenase 2 Family Member (ALDH2) is a critical member of the aldehyde dehydrogenase family. Many researchers have found that ALDH2 mutations play an important role in the activation of hepatocellular carcinoma carcinogenic pathways. However, the clinicopathological meaning of ALDH2 in HCC and its relation with immune infiltration is still indistinguishable. In this study, we explored the expression of ALDH2 in 41 HCC tissues by immunohistochemistry. The clinicopathological meaning and molecular function of ALDH2 were analyzed and evaluated through comprehensive bioinformatics. ALDH2 expression in HCC was validated in TCGA, GEO and Oncomine databases, and a survival of ALDH2 based on TCGA database was analysed. LinkedOmics was used to classify the co-expressed genes of ALDH2 and its regulatory factors. The relation between ALDH2 and immune infiltration in HCC was further explored by TIMER. IHC results showed decreased levels of ALDH2 in HCC tumor tissues compared with corresponding normal liver tissues. The pathological grade and prognosis of patients with low expression of the ALDH2 gene were worse. Bioinformatics analysis results showed that ALDH2 was considerably down-regulated in cancer tissues compared with corresponding normal liver tissues in 8 GEO series and TCGA profile (all

Indexed as

ALDH2Hepatocellular carcinomaimmune infiltrationimmunotherapyprognostic markers

Identifiers

PMID34873463
PMCPMC8640816
OpenAlexW4206856020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.